Helixgate

Helixgate

Uncategorized

Biotech layoffs are easing, but is the worst over?

BioNTech is one of the most recent companies to announce cuts, but the pace of job losses is slowing.

Read More

Published

on

BioNTech is one of the most recent companies to announce cuts, but the pace of job losses is slowing.

Read More

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Uncategorized

New home for Novo’s Parkinson’s cell therapy; GSK turns to China for hep B drug

Published

on

Plus, label expansions for two drugs targeting rare diseases, and Genmab scraps a Phase 1 cancer trial:

🧠 Novo’s Parkinson’s cell therapy finds a biotech home: Novo Nordisk has found a home for an early-stage …

Continue Reading

Uncategorized

STAT+: Astellas treatment offers new hope to a devastated rare disease community

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

There’s fresh turmoil at the very top of the FDA: All weekend, questions have swirled over whether Commissioner Marty Makary will be ousted.

Also, we have a resurrected gene therapy effort in a once-devastated rare disease program, and underwhelming Alzheimer’s drug adoption. 

Continue to STAT+ to read the full story…

Read More

Published

on

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

There’s fresh turmoil at the very top of the FDA: All weekend, questions have swirled over whether Commissioner Marty Makary will be ousted.

Also, we have a resurrected gene therapy effort in a once-devastated rare disease program, and underwhelming Alzheimer’s drug adoption. 

Continue to STAT+ to read the full story…

Read More

Continue Reading

Uncategorized

Braveheart Bio’s Hengrui-licensed cardiac drug scores second clinical win

Published

on

Braveheart Bio said Monday that the heart muscle therapy it licensed from China’s Jiangsu Hengrui Pharmaceuticals has succeeded in a mid-stage trial for the same condition in which Cytokinetics recently scored a

Continue Reading
Advertisement

Trending